簡體|繁體
Xalatan Latanoprost Eye Drops
Specification
0.005%(2.5ml:125μg)
Introduction

Xalatan is the first PG eyedrops launched on the market in the world by Pfizer. It is also the first-line drug for the treatment of glaucoma in most of the countries and regions. Essex Medipharma is responsible for the promotion and sale of the product in the mainland China.

Mechanism

The active ingredient latanoprost is the analogue of prostaglandin F2, which is a selective prostaglandin FP receptor agonist that can reduce intraocular pressure by enhancing the outflow of aqueous humor. For human being, the intraocular pressure (IOP) starts to drop down 3 or 4 hours later after drug administration, and the maximum effect can be achieved 8 to 12 hours later. Intraocular pressure reduction effect can last at least 24 hours. Studies on animals and human showed that the main action mechanism of the drug is to increase the bypass flow of uveoscleral of aqueous humor, but its benefit to the outflow of aqueous humor in human eyes by reducing the drainage resistance was also reported.

Features

The first line drug recommended by the guidelines in many countries;
Reducing intraocular pressure over 25%;
IOP meets standard for 24 hours after drug administration;
The first PG drug with the largest prescription in the world;
High medication persistence rate, as 81.6% of patients can adhere to medication for two years.

Application

The product is indicated for the reduction of elevated IOP of patients with open-angle glaucoma and ocular hypertension.

网上购买彩票 时时彩赚钱秘籍 pk10十选九码如何稳赢 王者捕鱼下载 农村埋人能赚钱吗 淘宝里面的我要赚钱 2002福彩3d开奖数据 棋牌测评网现金棋牌官方网站 快速时时彩开奖号码 7月23日体彩11选5 正宗杭州麻将单机版app 金沙棋牌游戏官方网站 炒股第100天 老虎机怎么玩稳赚 工商管理最赚钱 猜大小无敌版 老重庆时时采彩开奖